المؤلفون: Hendrik P. Verschuur, Rudolf G. J. Wiggenraad, Frank J. F. Jeurissen, Lucia B. Vrolijk, Marije Slingerland, Camiel L.M. de Roij van Zuijdewijn

المساهمون: Nephrology, ACS - Diabetes & metabolism

المصدر: Clinical otolaryngology, 44(2), 172-175. Wiley-Blackwell
Clinical Otolaryngology, 44(2), 172-175. WILEY

مصطلحات موضوعية: Male, medicine.medical_specialty, Cetuximab, Antineoplastic Agents, Antineoplastic Agents, Immunological, Enteral Nutrition, Antineoplastic Agents, Immunological/administration & dosage, Immunological/administration & dosage, PEG ratio, medicine, Humans, Aged, Cetuximab/administration & dosage, Retrospective Studies, Gastrostomy, Tube dependency, business.industry, Head and neck cancer, Head and Neck Neoplasms/drug therapy, Retrospective cohort study, Chemoradiotherapy, Gastrostomy/adverse effects, Middle Aged, medicine.disease, Enteral Nutrition/adverse effects, Otorhinolaryngology, Head and Neck Neoplasms, Female, Radiology, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d9196d8e60138d57b1080b63d7da2eTest
https://doi.org/10.1111/coa.13282Test

المؤلفون: Marco Zezza, Nelly Pitteloud, Haithem Chtioui, Laura Marino, Faiza Lamine, Carine Mekoguem, Christophe Kosinski

المصدر: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Skin Neoplasms, Combination therapy, Diabetic ketoacidosis, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Case Report, Ipilimumab, Type 2 diabetes, Immune checkpoint inhibitor, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Endocrinopathies, Melanoma, Autoimmune adverse events, Aged, 80 and over, Type 1 diabetes, lcsh:RC648-665, business.industry, Type 2 Diabetes Mellitus, General Medicine, Middle Aged, medicine.disease, Acute Disease, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Diabetes Mellitus, Type 1/diagnosis, Diabetes Mellitus, Type 1/pathology, Female, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Melanoma/drug therapy, Melanoma/pathology, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Diabetes Mellitus, Type 1, Nivolumab, 030220 oncology & carcinogenesis, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a722f98fa2436ff73199210f96e9153Test
https://doaj.org/article/5e85b5b762c841489b8519ccf9b5cc94Test

المؤلفون: Davide Rossi, Rahel Schwotzer, Raphael Heimgartner, Andreas J. Flammer, Georg Stussi, Bernhard Gerber, Guido Ghilardi, Erika Lerch, Christine Waibel, Harald Seeger, Clemens Caspar, Stefanie Pederiva, Thomas Fehr, Elena Bianchi, Markus G. Manz, Sofie Brouwers

المساهمون: Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Clinical Pharmacy, Experimental Pharmacology, University of Zurich, Schwotzer, Rahel

المصدر: Hematological Oncology. 37:595-600

مصطلحات موضوعية: Male, Cancer Research, 2720 Hematology, Immunoglobulin Light-chain Amyloidosis/diagnosis, Severity of Illness Index, Gastroenterology, Antineoplastic Agents, Immunological, 0302 clinical medicine, Bone Marrow, Recurrence, Immunoglobulin Light-chain Amyloidosis, 10035 Clinic for Nephrology, 1306 Cancer Research, Bortezomib, Amyloidosis, Antibodies, Monoclonal, Hematology, General Medicine, Middle Aged, Treatment Outcome, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Retreatment, 10209 Clinic for Cardiology, 2730 Oncology, Female, medicine.drug, Adult, medicine.medical_specialty, Plasma Cells, Infections/etiology, 610 Medicine & health, Infections, Antibodies, Monoclonal/administration & dosage, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Refractory, Internal medicine, medicine, AL amyloidosis, Humans, Lymphocyte Count, Adverse effect, Aged, Lenalidomide, Bone Marrow/metabolism, business.industry, Daratumumab, medicine.disease, Drug Resistance, Neoplasm, 10032 Clinic for Oncology and Hematology, Plasma Cells/pathology, Bone marrow, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afce2e4f761edbd1d13b6d39b85360dfTest
https://doi.org/10.1002/hon.2677Test

المؤلفون: Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, Brichard, Bénédicte

المساهمون: Clinical sciences, Growth and Development, Pediatrics, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique

المصدر: The New England journal of medicine, Vol. 382, no. 23, p. 2207-2219 (2020)
N Engl J Med

مصطلحات موضوعية: Oncology, Male, Pediatrics, medicine.medical_treatment, Lymphoma, B-Cell/drug therapy, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Rituximab/administration & dosage, Antineoplastic Agents, Immunological, 0302 clinical medicine, Neutropenia/chemically induced, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Child, Infusions, Intravenous, Medicine(all), General Medicine, Progression-Free Survival, Mature B-Cell Non-Hodgkin's Lymphoma, Rituximab, Female, Lymph, medicine.drug, medicine.medical_specialty, Lymphoma, B-Cell, Neutropenia, Adolescent, Child, preschool, Infections/etiology, MEDLINE, Infections, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cancer, medicine.disease, Lymphoma, Clinical trial, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::744223cf26167119db29672da134c6f0Test
https://doi.org/10.1056/nejmoa1915315Test

المؤلفون: Yang Meng, Neil Roskell, Andrew Walker, Helen Johnson, D. Lee, John Ellis, Zoe Philips, N. Hertel, E. Morais

المصدر: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4Test

مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, Cost effectiveness, Cost-Benefit Analysis, Economics, Econometrics and Finance (miscellaneous), Kaplan-Meier Estimate, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Skin Neoplasms/drug therapy, Melanoma/drug therapy, 030212 general & internal medicine, Vemurafenib, Melanoma, Health Policy, Imidazoles, Age Factors, Ipilimumab/economics, Middle Aged, Markov Chains, Nivolumab/administration & dosage, Dacarbazine, Nivolumab, Models, Economic, Health Resources/economics, 030220 oncology & carcinogenesis, Disease Progression, Health Resources, Female, Quality-Adjusted Life Years, medicine.drug, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Imidazoles/economics, Ipilimumab, Disease-Free Survival, 03 medical and health sciences, Sex Factors, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, Proto-Oncogene Proteins B-raf/genetics, medicine, Humans, Oximes/economics, Survival analysis, Aged, business.industry, Vemurafenib/economics, Dacarbazine/economics, Dabrafenib, Clinical trial, Health Expenditures, business, Antineoplastic Combined Chemotherapy Protocols/economics

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbba7ec0a8309e03b0b8e6ffb8f01a95Test
https://doi.org/10.1007/s10198-018-0964-4Test

المؤلفون: Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters

المصدر: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, CNS demyelination, Immunology, Remission, Spontaneous, Spontaneous remission, Case Report, Metastatic melanoma, lcsh:RC254-282, Asymptomatic, 03 medical and health sciences, Immune checkpoint inhibitors, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune related adverse events, Internal medicine, medicine, Image Processing, Computer-Assisted, Immunology and Allergy, Humans, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Asymptomatic Diseases, Demyelinating Diseases/diagnosis, Demyelinating Diseases/etiology, Magnetic Resonance Imaging, Melanoma/complications, Melanoma/diagnosis, Melanoma/drug therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Neurological toxicities, Nivolumab, Melanoma, Pharmacology, business.industry, Immunotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Hyperintensity, 030104 developmental biology, 030220 oncology & carcinogenesis, Molecular Medicine, medicine.symptom, business, Demyelinating Diseases

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90Test
https://pubmed.ncbi.nlm.nih.gov/31791418Test

المؤلفون: Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci

المصدر: Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998Test

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Skin Neoplasms, Time Factors, Medizin, Gastroenterology, law.invention, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Skin Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Melanoma/drug therapy, Ipilimumab/administration & dosage, Melanoma, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, 3. Good health, Nivolumab/administration & dosage, Nivolumab, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, Rapid Communication, medicine.drug, Adult, medicine.medical_specialty, Ipilimumab, Drug Administration Schedule, 03 medical and health sciences, Young Adult, Antineoplastic Agents, Immunological/administration & dosage, Double-Blind Method, Internal medicine, medicine, Humans, Dosing, Progression-free survival, Adverse effect, Aged, Neoplasm Staging, business.industry, Clinical trial, 030104 developmental biology, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7100d36b125a105d0de169d7144e1e3eTest
https://pubmed.ncbi.nlm.nih.gov/30811280Test

المؤلفون: Pauline De Bruyn, Véronique Del Marmol, Alain Le Moine, Piet Ost, Arnaud Devresse, Dirk Van Gestel, Sandrine Aspeslagh, Lieve Brochez, Vibeke Kruse, Hans Van Vlierberghe

المساهمون: Medical Oncology, Laboratory for Medical and Molecular Oncology, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie

المصدر: Current opinion in oncology, 31 (2
Current Opinion in Oncology, Vol. 31, no. 2, p. 54-64 (2019)

مصطلحات موضوعية: Graft Rejection, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Programmed Cell Death 1 Receptor, MEDLINE, Organ transplantation, Liver Neoplasms/drug therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, medicine, Humans, CTLA-4 Antigen, Immunosuppressive Agents/administration & dosage, business.industry, Kidney Transplantation/methods, Liver Neoplasms, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Graft Rejection/immunology, Sciences bio-médicales et agricoles, Kidney Transplantation, CTLA-4 Antigen/antagonists & inhibitors, Advanced cancer, Immune checkpoint, Blockade, Cancérologie, 030104 developmental biology, surgical procedures, operative, Allograft rejection, 030220 oncology & carcinogenesis, business, Immunosuppressive Agents

وصف الملف: 1 full-text file(s): application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c535eda7482de37df51437a7bb163cTest
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/284038Test

المؤلفون: Magdalena Jadwiga Utsch, Anna Krilova, Özlem Türeci, Martin Schuler, Karl Dhaene, Markus Jerling, Christoph Rohde, Stefan Bauer, Tobias Dechow, Ugur Sahin, Heike Richly, Christoph Huber

المساهمون: Supporting clinical sciences, Experimental Pathology

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, Time Factors, Esophageal Neoplasms, Maximum Tolerated Dose, medicine.medical_treatment, Medizin, Gastroenterology, Antibodies, Monoclonal/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Pharmacokinetics, Antineoplastic Agents, Immunological/administration & dosage, Stomach Neoplasms, Internal medicine, Germany, medicine, Humans, Drug Dosage Calculations, Adverse effect, Infusions, Intravenous, Aged, business.industry, Cancer, Antibodies, Monoclonal, Esophagogastric Junction/drug effects, Immunotherapy, Middle Aged, medicine.disease, Latvia, ddc, 030104 developmental biology, Treatment Outcome, Oncology, Tolerability, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, Female, Stomach Neoplasms/drug therapy, Esophagogastric Junction, Esophageal Neoplasms/drug therapy, business, Progressive disease

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb9949f013111d7e7dd98d889459c98Test
https://doi.org/10.1016/j.ejca.2018.05.007Test

المؤلفون: Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma

المساهمون: Hospital Universitario 12 de Octubre, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University

المصدر: CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126Test
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE

مصطلحات موضوعية: 0301 basic medicine, Anticuerpos Monoclonales, Male, Indoles, MULTICENTER, Supervivencia sin Enfermedad, urologic and male genital diseases, THERAPY, 0302 clinical medicine, Antineoplastic Agents, Immunological, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Sunitinib, Tasa de Supervivencia, Ipilimumab/administration & dosage, Masculino, Aged, 80 and over, Persona de Mediana Edad, KIDNEY CANCER, Adulto, Antibodies, Monoclonal, PHASE-III TRIAL, General Medicine, Indoles/administration & dosage, Middle Aged, OPEN-LABEL, Kidney Neoplasms, Humanos, Axitinib, Survival Rate, Kidney Neoplasms/drug therapy, Nivolumab, 030220 oncology & carcinogenesis, Antineoplásicos Inmunológicos, medicine.drug, Protocolos de Quimioterapia Combinada Antineoplásica, Adult, Risk, medicine.medical_specialty, Análisis de Supervivencia, Anciano, Urology, Ipilimumab, Riesgo, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, PAZOPANIB, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Syöpätaudit - Cancers, medicine, Carcinoma, Humans, Pyrroles, SYMPTOM INDEX, Carcinoma de Células Renales, Survival rate, Carcinoma, Renal Cell, Survival analysis, Aged, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Pyrroles/administration & dosage, UNTREATED MELANOMA, medicine.disease, Pirroles, Survival Analysis, Anciano de 80 o más Años, 1ST-LINE TREATMENT, 030104 developmental biology, Carcinoma, Renal Cell/drug therapy, Quality of Life, Calidad de Vida, INTERFERON-ALPHA, business, Neoplasias Renales

وصف الملف: application/pdf; fulltext

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4Test
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinomaTest(9d613da7-a490-4e1e-940a-79cc1309b512).html